vVardis Secures $175m Funding Round Ahead of Planned NYSE IPO

RecentNews.uk

vVardis raises $175 million in fresh funding ahead of its planned New York Stock Exchange IPO.

The capital raise supports global distribution, clinical trials, and commercial scaling.

The move highlights the continuing preference for Wall Street listings among international biotech firms.

Formal SEC prospectus filings and investor roadshows are expected to follow.

Should European biotech companies prioritize listing on European stock exchanges instead of Wall Street?

Tap below to vote and see what others think.